MYC and neuroblastoma: In a report from the Neuroblastoma Group of the International Society of Paediatric Oncology Europe (SIOPEN) MYC-N amplified NB accounted for only 10% of affected infants.[15] Here, infants with MYC-N amplified NB had a poor outcome despite intensified therapy with a 2-year overall survival of 30% (SE, 0.08) only and a median survival time of 12 months with deaths due to disease being the most frequent events.